The abstract is read at the publisher; the summary is JClub's.
Prophylactic fingolimod (0.3 mg/kg/day) given for 21 days in male Wistar albino rats significantly reduced proliferative vitreoretinopathy severity after intravitreal autologous PRP injection.
- Why it matters: PVR remains a vision-threatening complication with limited preventive options, and inflammation and immune activation are linked to its development.
- What they did: Thirty-two rats were randomized into Control, Fingolimod, PVR, and PVR + Fingolimod groups (n = 8 each); PVR was induced by intravitreal PRP, and fingolimod was delivered by oral gavage for 21 days. Histopathology assessed retinal fold grades, ERM scoring, retinal detachment staging, vessel counts, retinal thickness, vitreoretinal traction membrane presence, and retinal-layer disruption.
- The result: In the PVR + Fingolimod group, retinal fold grades were lower than in the PVR group (1.12 ± 0.99 vs. 3.25 ± 1.04), with no overt systemic toxicity or weight loss based on body weight monitoring. This proof-of-concept supports fingolimod as a prophylactic candidate for PVR prevention in this rat model.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.